Arbutus Biopharma (ABUS) Long-Term Investments (2014 - 2024)

Arbutus Biopharma has disclosed Long-Term Investments across 11 years of filings, most recently posting $3.0 million for Q3 2024.

• Long-Term Investments for Q3 2024 came in at $3.0 million, down 71.76% year-over-year; the trailing twelve-month figure through Sep 2024 was $3.0 million (down 71.76% YoY), and the FY2023 annual result was $6.3 million, down 83.18% from the prior year.
• Long-Term Investments came in at $3.0 million for Q3 2024 at Arbutus Biopharma, down from $6.5 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $55.4 million in Q3 2022 to a low of $1.6 million in Q2 2020.
• The 5-year median for Long-Term Investments is $31.8 million (2023), against an average of $23.9 million.
• Across the five-year window, Long-Term Investments plunged 88.87% in 2020 and jumped 2130.5% in 2021, its largest moves.
• Arbutus Biopharma's Long-Term Investments stood at $1.6 million in 2020, then surged by 2130.5% to $35.7 million in 2021, then climbed by 4.69% to $37.4 million in 2022, then slumped by 83.18% to $6.3 million in 2023, then tumbled by 52.83% to $3.0 million in 2024.
• The last three Long-Term Investments figures came in at $3.0 million (Q3 2024), $6.5 million (Q2 2024), and $8.7 million (Q1 2024), per Business Quant data.